New cancer drug NX-1607 enters first human trials

NCT ID NCT05107674

Recruiting now Disease control Sponsor: Nurix Therapeutics, Inc. Source: ClinicalTrials.gov ↗

First seen Jun 26, 2026 · Last updated Jun 26, 2026

Summary

This early-stage trial tests a new drug called NX-1607 in adults with advanced cancers that have not responded to standard treatments. The study aims to find a safe dose and see if the drug can shrink tumors. It includes people with several cancer types, such as ovarian, lung, and melanoma.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: NX-1607 (a CBL-B inhibitor) and paclitaxel
What this could lead to: If successful, this could point toward a new treatment option for several advanced cancers that have not responded to standard therapies.
What could go wrong: This is an early Phase 1 trial, so safety and effectiveness are not yet established. The drug may cause side effects or fail to shrink tumors.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

Carcinoma, Ovarian Epithelial castration-resistant prostate carcinoma cervical cancer diffuse large B-cell lymphoma gastric cancer gastric neoplasm gastroesophageal cancer head and neck squamous cell carcinoma malignant pleural mesothelioma Mesothelioma, Malignant neoplasm Neoplasm Metastasis non-small cell lung carcinoma ovarian cancer Richter transformation Squamous Cell Carcinoma of Head and Neck transitional cell carcinoma triple-negative breast carcinoma Uterine Cervical Neoplasms

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

CERVICAL CANCER DIFFUSE-LARGE B-CELL LYMPHOMA (DLBCL) GASTRIC CANCER GASTROESOPHAGEAL JUNCTION (GEJ) CANCER HEAD AND NECK SQUAMOUS CELL CARCINOMA MALIGNANT PLEURAL MESOTHELIOMA (MPM) METASTATIC CASTRATION-RESISTANT PROSTATE CANCER (MCRPC) METASTATIC OR UNRESECTABLE MELANOMA METASTATIC UROTHELIAL CARCINOMA MICROSATELLITE STABLE COLORECTAL CARCINOMA NON-SMALL CELL LUNG CANCER (NSCLC) OVARIAN CANCER, EPITHELIAL RICHTER TRANSFORMATION TRIPLE-NEGATIVE BREAST CANCER (TNBC)

Contacts and locations

Locations

Addenbrookes Cambridge University Hospital
RECRUITING

Cambridge, CB2 0QQ, United Kingdom
Beatson West of Scotland Cancer Centre
RECRUITING

Glasgow, G12 0YN, United Kingdom
Churchill Hospital
COMPLETED

Oxford, OX3 7LE, United Kingdom
City of Hope
COMPLETED

Duarte, California, 91010, United States
Fred Hutchinson Cancer Center
RECRUITING

Seattle, Washington, 98109, United States
MD Anderson Cancer Center
RECRUITING

Houston, Texas, 77030, United States
Northern Centre for Cancer Care
RECRUITING

Newcastle, NE7 7DN, United Kingdom
Royal Marsden Hospital NHS Foundation Trust
RECRUITING

Sutton, Surrey, SM2 5PT, United Kingdom
Sarah Cannon Research Institute
RECRUITING

London, W1G 6AD, United Kingdom
The Christie NHS Foundation Trust
RECRUITING

Manchester, M20 4BX, United Kingdom
University of California, San Francisco
RECRUITING

San Francisco, California, 94158, United States
University of Chicago
RECRUITING

Chicago, Illinois, 60637, United States
University of Colorado School of Medicine
RECRUITING

Aurora, Colorado, 80045, United States
University of North Carolina
RECRUITING

Chapel Hill, North Carolina, 27599, United States
University of Oklahoma
RECRUITING

Oklahoma City, Oklahoma, 73104, United States
University of Southern California
RECRUITING

Los Angeles, California, 90007, United States
University of Virginia
RECRUITING

Charlottesville, Virginia, 22908, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.